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Abstract
Background: Serum selenium level (s-Se) has been associated with prostate cancer (PrCa) risk. We investigated the
relation between s-Se, smoking and non-screening detected PrCa and explored if polymorphisms in two DNA
repair genes: OGG1 and MnSOD, influenced any effect of s-Se.
Methods: ULSAM, a population based Swedish male cohort (n = 2322) investigated at age 50 for s-Se and s-Se
influencing factors: serum cholesterol, erythrocyte sedimentation rate and smoking habits. At age 71 a subcohort,
(n = 1005) was genotyped for OGG1 and MnSOD polymorphisms.
Results: In a 34-year-follow-up, national registries identified 208 PrCa cases further confirmed in medical records.
Participants with s-Se in the upper tertile had a non-significantly lower risk of PrCa. Smokers with s-Se in the two
lower tertiles (≤80 μg/L) experienced a higher cumulative incidence of PrCa than smokers in the high selenium
tertile (Hazard Ratio 2.39; 95% CI: 1.09-5.25). A high tertile selenium level in combination with non-wt rs125701 of
the OGG1 gene in combination with smoking status or rs4880 related variation of MnSOD gene appeared to
protect from PrCa.
Conclusions: S-Se levels and smoking habits influence long-term risk of PrCa. Smoking as a risk factor for PrCa in
men with low s-Se is relevant to explore further. Exploratory analyses of variations in OGG1 and MnSOD genes
indicate that hypotheses about patterns of exposure to selenium and smoking combined with data on genetic
variation in genes involved in DNA repair can be valuable to pursue.
Background
Oxidative DNA base modification likely plays an impor-
tant role in prostate carcinogenesis [1]. Both endogen-
ous and exogenous antioxidants act interdependently in
preventing clinically significant prostate cancer [2]. The
selenoproteins active in oxidative DNA damage repair
need the antioxidant selenium to be fully effective [3-8].
High serum selenium levels correlate with decreased
incidence of cancer in general [9,10], and prostate can-
cer in particular [11-16], an association by some found
to be mainly present in smokers [17]. Low serum sele-
nium levels inversely relate to overall accumulated DNA
damage [18] and selenoproteins are highly expressed in
the prostate [19].
Despite that selenium thus theoretically may be a can-
didate anti-oxidant to use for prevention, the recent
SELECT trial [20] - a large interventional study with
selenium supplementation and/or vitamin E supplemen-
tation to reduce the risk of prostate cancer - was prema-
turely ended due to lack of effect. However, selenium
may still be protective in a subset of men with specific
genetic polymorphisms of the MnSOD gene [2] or in
men with low baseline levels of serum selenium [21-23]
which was not studied in SELECT but could be relevant
to study further in light of recent findings[24].
The role of tobacco smoking in prostate cancer etiol-
ogy is still unclear [25,26] but as smoking causes oxida-
tive damage [27,28] and also is associated with lower
serum selenium levels [29,30] a relation between smok-
ing and prostate cancer seems biologically plausible.
Genes of interest to a relation between selenium and
prostate cancer risk include those involved in DNA
* Correspondence: birgitta.grundmark@surgsci.uu.se
1Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Full list of author information is available at the end of the article
Grundmark et al. BMC Cancer 2011, 11:431
http://www.biomedcentral.com/1471-2407/11/431
© 2011 Grundmark et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.repair and oxidative stress. Oxidative stress triggers the
base mutation 8-oxoguanine (OG) in DNA [31]. Single
nucleotide polymorphisms (SNPs) in the gene coding
for 8-oxoguanine glucosylase (OGG1), a selective base
excision repair enzyme for OG-lesions [32], are asso-
ciated with cancer progression [33,34] with evidence
also for an association with prostate cancer [35-38].
Manganese superoxide dismutase (MnSOD)i st h ep r i -
mary antioxidant enzyme in mitochondria. A functional
SNP in the MnSOD gene, rs4880, modifies risk of pros-
tate cancer associated with serum levels of pre-diagnos-
tic selenium [2] although it not in itself was associated
with prostate cancer risk [39]. MnSOD enzyme activity
has a 56-fold range of values between polymorphic var-
iants [40].
The aim of our study was to investigate the association
between serum selenium levels at age 50 and later non-
screening detected prostate cancer in a population based
study with up to 34 years of individual follow up, and to
assess if smoking status at baseline modified this associa-
tion. In this cohort we also had information on factors
with a potential to decrease serum selenium levels: Ery-
throcyte sedimentation rate (ESR), total serum choles-
terol [41], and also of body mass index (BMI). In
addition, we explored as a hypotheses generating analysis
in a subcohort if polymorphism in the genes OGG1 and
MnSOD influenced any effect of serum selenium.
Methods
The study was approved by the Ethics Committee of the
Faculty of Medicine at Uppsala University and written
informed consent to participate was obtained from all
participants.
The source population of the study is a cohort in the
Uppsala Longitudinal Study of Adult Men (ULSAM). In
1970-1973, all male residents in Uppsala county in Janu-
ary 1970, born in 1920-24 (n = 2841) were invited to
take part in a prospective health survey aimed at identi-
fying risk factors for diabetes and cardiovascular disease.
Eighty two per cent (n = 2322) of the invited men parti-
cipated at baseline, at age 50, forming ULSAM [42].
The serum selenium level at age 50 was determined
for 2045 men in ULSAM and they constitute our study
base (figure 1). After 21 years of follow-up, at age 71,
the cohort was invited to a third cycle of investigation,
performed from 1991 to 1995, including 1 221 of 1681
men still alive in January 1991. At this third cycle of
investigation, blood samples for DNA extraction and
later genotyping were collected from 1052 men giving
consent for such sampling. Genotypes of OGG1 and
Figure 1 Participant flow chart. Flow chart of the investigated population of the study within the ULSAM cohort.
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The baseline mean serum levels of selenium, and two
factors negatively correlated to selenium concentration:
ESR and total serum cholesterol [41] did not differ
between the 1005 genotyped and the full cohort of 2045
men who at baseline had their serum selenium levels
determined. Therefore, the genotyped men were consid-
ered a representative sub-sample of the full cohort. Use
of the drug clozapine may decrease serum selenium
levels [43] but none of the participants reported use of
this drug at age 50, i.e. concurrently with the blood
sampling for selenium.
Baseline examinations at age 50
Blood samples were drawn after an overnight fast.
Serum concentrations were determined in samples that
had been stored frozen (-70°C). Selenium was deter-
mined in serum using the graphite-furnace atomic
absorption spectrometric method [44]. Fasting total cho-
lesterol concentrations was performed on a Technicon
Auto Analyzer type II [45] in 1981-82 on serum samples
up until then stored in liquid nitrogen since 1970-73.
ESR was determined by Westergren’sm e t h o d[ 4 6 ] .
Based on personal interview reports the men were char-
acterised as smokers or non-smokers (including ex-smo-
kers) according to smoking status at age 50. Further
sub-grouping of smoking data or stratifying by details of
smoking history was not feasible due to sample size.
Weight, height and BMI (kg/m
2) were measured
under standardized conditions [47]
Examinations at age 71
Four SNPs in proximity to the OGG1 gene were selected
for genotyping; rs125701, based on the findings by [48] and
another three SNPs distributed over the gene. The same
method was used for the MnSOD gene where rs2758331
for technical reasons was used as proxy for rs4880, with a
correlation coefficient (r
2) = 0.92, [39,49,50] and further
another five SNPs of the gene were investigated. The
selected SNPs were genotyped at the SNP Technology Plat-
form, Uppsala University, using the Golden Gate Assay
(Illumina Inc.) [51]. The genotypes conformed to Hardy-
Weinberg equilibrium according to a c
2 test (p > 0.05).
The reproducibility of the genotyping was 100% according
to duplicate assays for 2.7% of the genotypes.
Follow-up and outcome measures
Follow-up started at the examination in 1970-74 at age 50
and the censoring date for the present study was Decem-
ber 31, 2003, with a mean of 26.5 years of observation for
the full cohort of 2045 men (54243 person years) and a
mean of 31.1 years of observation for the genotyped 1005
men (31290 person years). To identify invasive prostate
cancer (by International Classification of Diseases and
Related Health Problems, 10th Revision, ICD-10; C61) we
linked the unique personal identification numbers to the
nationwide Population Register, the Cancer Register, the
Hospital Discharge Register and the Causes of Death Reg-
ister. The Cancer Register and the Causes of Death Regis-
ter were established in 1958 while the Hospital Discharge
Register covering all somatic inpatient health care was
established in 1987. Reporting to these registries is com-
pulsory. The coverage of prostate cancer in the Cancer
Register is more than 95% [52] and for the other three reg-
isters 99% or more [53-55]. Identified prostate cancer
cases were confirmed by reviewing the medical records
whereby clinical details of the disease were collected
(Table 1). In seven cases, where the medical records could
not be retrieved, the diagnosis was verified by data in the
National Prostate Cancer Registry, a nationwide clinical
database started in 1997 [56].
The practice of PSA testing was during the period of
follow-up restrictive both nationally and in the region of
the Uppsala University Hospital. General screening is
still not recommended and uncommon in men who, like
in this cohort now, are well above 80 years of age.
Statistical methods
The full cohort of 2045 men with full baseline measure-
ments was analyzed for the main outcome of prostate can-
cer in relation to selenium levels and smoking. The 1005
genotyped men at age 71 were also analyzed separately to
explore any effect modifications of polymorphisms in
OGG-1 or MnSOD. Smoking status and BMI influence life
span expectancy and constitute competing forces of mor-
tality with prostate cancer. The men in the full cohort and
in the genotyped subcohort were divided into tertiles
according to their serum selenium concentrations, sele-
nium influencing factors (Table 2) and BMI.
Risks of a) prostate cancer and b) death without a
diagnosis of prostate cancer were calculated by means of
cumulative incidence curves [57] censoring for end of
follow up without events and considering the both types
of endpoints a) and b) as competing events.
Competing risk proportional hazards models were
determined for the sub-distribution of prostate cancer
through competing risk regression [58] considering
death without a diagnosis of prostate cancer as a com-
peting risk. Hazard ratios derived from proportional
hazards models were used as the estimator of relative
risk (RR) of the effect of serum selenium divided into
tertiles, smoking habits, and SNPs.
Results
Prostate cancer characteristics
During follow-up 208 men (10.2%) in the full cohort of
2045 and 126 of the 1005 genotyped men (12.5%)
(OGG1), were diagnosed with prostate cancer.
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Page 3 of 11Table 1 Clinical characteristics of the men diagnosed with prostate cancer (PrCa) in the full cohort and in the
genotyped subcohort.
PrCa in full cohort (n = 208) PrCa in subcohort (n = 126)
Age at diagnosis: median (range) 73 (57-83.0) 75 (59-82.0)
Diagnosis confirmed by: n (%)
Histology 164 (78.8) 112 (88.9)
Cytology 33 (15.9) 11 (8.7)
Clinical examination only 3 (1.4) 1 (0.8)
Information missing 8 (3.8) 2 (1.6)
Diagnosis suspected from: n(%)
PSA Screening 2 (1.0) 2 (1.6)
LUTS** 127 (61.1) 85 (67.5)
Other urological or skeletal symptoms 33 (15.9) 18 (14.3)
Incidentally discovered† 15 (7.2) 10 (7.9)
Other 7 (3.4) 6 (4.8)
Information missing 24 (11.5) 5 (4.0)
PSA-level***, ng/mL n (%)
≤4 8 (3.8) 6 (4.8)
4.1-10 24 (11.5) 18 (14.3)
10.1-20 31 (14.9) 25 (19.8)
20.1-100 41 (19.7) 33 (26.2)
> 100 23 (11.1) 14 (11.1)
Information missing 81 (38.9) 30 (23.8)
T-stage‡, n (%)
T0/T1ab 28 (13.5) 20 (15.9)
T1c 25 (12.0) 19 (15.1)
T2 89 (42.8) 55 (43.7)
T3-4 47 (22.6) 27 (21.4)
TX/Information Missing 19 (9.1) 5 (4.0)
N-stage‡, n (%)
N0 32 (15.4) 22 (17.5)
N1 12 (5.8) 5 (4.0)
NX 142 (68.3) 90 (71.4)
Information missing 22 (10.6) 9 (7.1)
M-stage‡in combination with PSA, n (%)
M0 88 (42.3) 61 (48.4)
MX, PSA ≤20 11 (5.3) 11 (8.7)
MX, 20 < PSA≤100 26 (12.5) 17 (13.5)
M1/PSA > 100 48 (23.1) 22 (17.5)
Information missing 35 (16.8) 15 (11.9)
Gleason score*, n(%)
2-6 50 (41.3) 41 (45.6)
7 20 (16.5) 17 (18.9)
8-10 31 (25.6) 26 (28.9)
Information missing 20 (16.5) 6 (6.7)
* WHO grade translated into Gleason score G1 = 2-6, G2 = 7, G3 = 8-10 in 42 cases
** Lower urinary tract symptoms.
*** Prostate specific antigen
†Incidentally discovered under investigation for symptoms not related to the urinary tract
‡As classified by the International Union Against Cancer (UICC)
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diagnosed with prostate cancer in the full cohort and in
the genotyped subcohort. In the full cohort the mean
age at diagnosis was 73 years. A large proportion of
men in the full cohort, 78.8%, were diagnosed by biopsy,
either by trans-rectal ultrasound (TRUS) guided core
needle biopsies or by surgery, predominately after trans-
urethral resection of the prostate. Seventy-six percent of
the men in the full cohort experienced symptoms lead-
ing to medical consultation and a diagnosis of prostate
cancer. Dominating symptoms leading to diagnosis were
lower urinary tract symptoms, skeletal pain, impotence
or deteriorating general condition. PSA measurement at
diagnosis was available for 61.1% in the full cohort. In
t h ef u l lc o h o r te i g h tm e nh a daP S Av a l u ea td i a g n o s i s
below 4 μg/L. Only 25.5% of the men had a non-palp-
able primary tumour (T0-T1c) at diagnosis while 22.6%
had T3 and T4 tumours, 47.6% of men in the full cohort
had no confirmed metastases or an unknown metastasis
status with PSA below or equal to 20 ng/mL. Gleason
scores - including WHO grades for cytology verified
cases translated into Gleason score - was 6 or below in
41.3% of the men of the full cohort.
Baseline measurements in relation to risk of prostate
cancer
Table 2 presents the unadjusted relative risk (RR) of pros-
tate cancer for baseline tertiles of serum selenium, ESR,
serum total cholesterol, BMI and for smoking status in the
full cohort and in the subcohort of genotyped men. The
mean serum selenium level in the genotyped men was
77.4 μg/l, considered a normal level for Europe but low
when compared to levels in North America. None of the
point estimates for tertiles differed statistically significantly
from unity. However, for the upper two tertiles of serum
selenium, serum total cholesterol and ESR all estimates
were numerically below unity with the exception of the
highest tertile of ESR for the genotyped men. Trend tests
for the estimates were all non-significant. The genotyped
men in the upper tertile of serum selenium presented with
the lowest risk estimate of developing prostate cancer (RR
0.72; 95% CI; 0.46-1.12). Adjustments by baseline tertiles
of ESR and total cholesterol level did not influence the
prostate cancer risk estimates for the tertiles of serum
selenium (data not shown).
T h en o n - s m o k e r sa n dm e ni nt h em i d d l et e r t i l eo f
BMI (23.5-26.0) at 50 years of age, appeared to have a
Table 2 Prostate cancer risk by subgroups
Full cohort Genotyped men
NonPrCa* PrCa PrCa-risk NonPrCa PrCa PrCa-risk
Serum selenium(μg/l) N % N % RR** 95% CI*** N % N % RR 95% CI
≤70 675 (36.7) 84 (40.4) Ref - 295 (33.6) 48 (38.1) Ref -
70.1-81.0 588 (32.0) 65 (31.2) 0.89 (0.65 - 1.24) 299 (34.0) 46 (35.7) 0.93 (0.62 - 1.4)
81+ 574 (31.2) 59 (28.4) 0.83 (0.60 - 1.16) 285 (32.4) 33 (26.2) 0.72 (0.46 - 1.12)
Erythrocyte sedimentation rate, ESR(mm/h)
≤4.0 704 (38.3) 84 (40.4) Ref - 348 (39.6) 51 (40.5) Ref -
4.1-8.0 587 (32.0) 67 (32.2) 0.97 (0.70 - 1.33) 297 (33.8) 38 (30.2) 0.89 (0.58 - 1.35)
8+ 545 (29.7) 57 (27.4) 0.88 (0.63 - 1.23) 234 (26.6) 37 (29.4) 1.07 (0.7 - 1.62)
Total serum cholesterol(mmol/l)
≤6.24 560 (30.5) 76 (36.5) Ref - 288 (32.8) 48 (38.1) Ref -
6.25-7.27 624 (34.0) 64 (30.8) 0.77 (0.55 - 1.07) 295 (33.6) 40 (31.7) 0.82 (0.54 - 1.25)
7.27+ 653 (35.5) 68 (32.7) 0.78 (0.56 - 1.08) 296 (33.7) 38 (30.2) 0.78 (0.51- 1.19)
BMI(kg/m
2)
≤23.4 605 (32.9) 61 (29.3) Ref - 296 (33.7) 39 (31.0) Ref -
23.5-26.0 567 (30.9) 78 (37.5) 1.34 (0.96 - 1.87) 285 (32.4) 50 (39.7) 1.31 (0.86 - 1.99)
26+ 665 (36.2) 69 (33.2) 1.03 (0.73 - 1.46) 298 (33.9) 37 (29.4) 0.96 (0.61 - 1.5)
Smoking
non-smoker 449 (24.4) 69 (33.2) Ref - 258 (29.4) 45 (35.7) Ref -
smoker 961 (52.3) 86 (41.3) 0.6 (0.44 - 0.83) 394 (44.8) 47 (37.3) 0.70 (0.46 - 1.05)
ex-smoker 427 (23.2) 53 (25.5) 0.82 (0.58 - 1.18) 227 (25.8) 34 (27.0) 0.87 (0.56 - 1.36)
Unadjusted relative risk (RR) of prostate cancer (PrCa) for baseline tertiles of selenium with 95% confidence intervals (CI), the two selenium level modifying
factors ESR, total cholesterol, BMI and for smoking status in the full cohort and in the genotyped men. The lowest tertiles and the non-smokers were useda s
references.
* Prostate cancer
** Relative risk
*** Confidence interval
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cohort as well as among the genotyped men (Table 2)
although not to a statistically significant level for all of
these groups.
Smoking, Serum Selenium and Prostate Cancer
S i n c et h er e s u l t sb ys m o k i n ga n dB M Im a yb ei n f l u -
enced by the increased risk of dying early among smo-
kers and among men with BMI over 26.0 or BMI under
23.4, we estimated the cumulative incidence of non-
prostate cancer death and prostate cancer occurrence by
smoking status in the full cohort, stratified by serum
selenium levels in the genotyped subcohort.
As illustrated in figure 2a and 2b, the cumulative inci-
dence of death without prostate cancer in the genotyped
subcohort was higher in smokers than in non smokers/ex-
smokers combined, independently of tertiles of serum sele-
nium (figure 2a low and middle serum selenium tertiles
combined, figure 2b high serum selenium tertile). As would
be expected from this result, due to their high incidence of
early non-prostate cancer death, smokers should have a
reduced cumulative incidence of prostate cancer, compared
to non- and ex-smokers combined. This pattern is observed
in Figure 2d for men in the upper tertile of serum selenium.
In contrast to this however, for men in the combined mid-
dle and lower serum selenium tertiles shown in Figure 2c,
Figure 2 a, b: Cumulative incidences of outcomes. Cumulative incidences of death without prostate cancer for smokers (black line) and non
smokers (grey line) by tertiles 1 and 2 combined (panel a) and tertile 3 (panel b) of serum selenium at baseline, 50 years of age in the
genotyped subcohort. Figure 2 c, d: Cumulative incidences of prostate cancer for smokers (black line) and non-smokers (grey line) by tertiles 1
and 2 combined (panel c) and tertile 3 (panel d) of serum selenium at baseline, 50 years of age in the genotyped subcohort. Tertile serum
selenium definitions; tertile 1 and 2 combined: ≤81 μg/L, and tertile 3: > 81 μg/L.
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equal to the cumulative incidence in non- and ex-smokers
combined, which thus would indicate that smoking
increases prostate cancer risk in men with lower serum
selenium levels. These findings for the cumulative incidence
are reflected in that smokers with serum selenium in the
two lower tertiles (≤80 μg/L) experienced a RR of 2.39;
(95% C.I. 1.09-5.25) for developing prostate cancer com-
pared to smokers in the high serum selenium tertile.
The results of the competing risk analysis were similar
to the results presented in figure 2, when the suggested
critical serum selenium threshold level 100 μg/l was
used instead of tertiles.
The genotyped subcohort
We further explored if SNPs in the OGG1 or MnSOD
gene modified the association between serum selenium
levels, smoking status and prostate cancer risk presented
in figure 2. The investigated SNPs in OGG1 per se did
not influence the risk for prostate cancer on a statisti-
cally significant level. Taking serum selenium levels into
account, presence of the A- allele of the SNP rs125701
in the OGG1gene, was observed to protect from prostate
cancer (figure 3) in the high tertile of serum selenium
compared to lower tertiles (p = 0.029). This was almost
solely an effect in smokers with a HR of 5.8 (95% C.I.
2.13-16.1) with the caveat of this being a small subgroup
of the whole cohort (n = 120).
The investigated MnSOD SNP, rs2758331, used as a
proxy for rs4880 similarly influenced the risk for pros-
tate cancer to a near significant level when taking serum
selenium levels into account (figure 4). Smoking did not
influence the MnSOD-selenium level association.
Discussion
In a study population where little PSA screening
occurred, we found a previously not reported relation
between serum selenium levels, smoking and prostate
cancer risk: Smokers with serum selenium levels in the
two lower tertiles (≤80 μg/L) experienced a higher
cumulative incidence of prostate cancer than smokers in
the high serum selenium tertile. In hypothesis generat-
ing explorative analyses, we found indications that the
association between serum selenium levels and prostate
cancer risk was modified by genetic polymorphisms, in
the OGG1 gene (rs125701) and MnSOD gene
(rs2758331- linked to rs4880).
The ULSAM cohort is population based and homoge-
nous as regards the ethnic background and the age of
the participants [42]. The participant rate was high and
the follow-up up to 34 years almost complete through
using linkage to national registers with high coverage.
Figure 3 a, b: Hazard ratios for prostate cancer by OGG1 genotype. Hazard ratios (HR), with 95% confidence interval, for later diagnosis of
prostate cancer in tertile 3 versus tertile 1(black line) and tertile 2 vs. tertile 1(gray line) of serum selenium levels at baseline, 50 years of age, by
OGG1 genotypes. To the left (a) from top are results for SNPs rs2304277 and rs125701 and at the bottom for all genotyped men and the full
cohort. To the right (b) from top are results for SNPs rs293796 and rs2472037. Tertile serum selenium definitions: tertile 1: ≤ 70 μg/L, tertile 2:
70.1- 81 μg/L and tertile 3: > 81 μg/L. “n” denotes number of participants in analysis.
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encing serum selenium levels including information on
smoking habits[42]. Only few prostate cancers were
detected by PSA-screening and our results thus mainly
pertain to clinically relevant prostate cancer with a high
risk of progress.
For cancer studies, ULSAM isc o m p a r a t i v e l ys m a l l
and modest or weak associations may go undetected:
our data indicate an overall modest inverse relation of
serum selenium level with prostate cancer risk, which
we could not substantiate. The serum selenium levels
and co- variates were measured at a median of 23
years before diagnosis, a disadvantage, which however
is shared with the other studies in the field [10,11,16].
In a Swedish population the range of selenium expo-
sure is limited, with few high serum selenium level
values. The size of the study implies that our analyses
of the interaction of gene polymorphism and serum
selenium levels are of an exploratory character.
Another disadvantage is that a proxy SNP was used for
the analysis of the main MnSOD polymorphism which
made a detailed analysis on a molecular level
unattainable.
Our finding of an increased risk for prostate cancer in
smokers with low serum selenium is a new finding. As
smoking increases oxidative damage, it is not biologi-
cally unreasonable. This relation may in other studies
have been masked by the strong competing risk of con-
comitant early death from other causes, mainly cardio-
vascular disease, predominantly in smokers. If smoking
is associated with both early death and risk of prostate
cancer later in life, conventional time to event analyses
may give a false impression that smoking protects from
prostate cancer since methods traditionally employed
assumes that censoring is non-informative. We noted
and analysed a similar pattern for obesity in the
ULSAM cohort [59]. This type of competing risk pro-
blem may be particularly evident in this study represent-
ing a pre-screening era where the median age at
diagnosis of prostate cancer was 73 years of age. Thus, a
screening program for prostate cancer introducing long
lead times may alter this pattern.
Our hypothesis generating results that serum selenium
levels and the polymorphic genes OGG1 and MnSOD
involved in the protection from oxidative stress, act con-
currently in the defence of prostate cancer development
Figure 4 a, b: Hazard ratios for prostate cancer by MnSOD genotype. Hazard ratios (HR), with 95% confidence interval, for later diagnosis of
prostate cancer in tertile 3 versus tertile 1(black line) and tertile 2 vs. tertile 1(gray line) of serum selenium levels at baseline, 50 years of age, by
MnSOD genotypes. To the left (a) from top are shown results for SNPs rs2758331, rs2842980, rs7855. To the right (b) from top are shown results
for SNPs, rs5746141, rs5746136 and rs4342445. Tertile serum selenium definitions: tertile 1: ≤ 70 μg/L, tertile 2: 70.1- 81 μg/L and tertile 3: > 81
μg/L. “n” denotes number of participants in analysis.
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[2,11,12,15,16,60]. A recent nested case-control study
within the Physicians Health Study [24] analyzing poly-
morphisms within the selenoprotein gene, SEP15 found
genetic variants associated with prostate cancer mortal-
ity and also modifying the association of serum selenium
with prostate cancer survival. If, as the recent report
suggest [24] and our study may be interpreted, only sub-
groups of men would benefit from high serum selenium
levels, then beneficial effects of supplementation in
interventional studies may pertain only to subgroups
and therefore be difficult to detect. There was an overall
lack of effect of selenium supplementation in the
SELECT trial [20]. The trial inclusion criteria did
neither enrich a study population with low baseline sele-
nium levels nor patients defined by pre-specified genetic
polymorphisms. The differences in results from the
interventional study, ours and another recent observa-
tional study [24] are not contradictory but rather
emphasize the possibility for interventional studies in
predefined groups of men with low selenium concentra-
tions and certain genetic profiles. Due to the limited
size of our study, the impact of genetic variation in rela-
tion to smoking being a risk factor for prostate cancer
was not possible to analyse further.
Conclusions
Our results indicate that when competing risks of death
are taken into account, middle age levels of serum sele-
nium and smoking habits give long term information
regarding the risk of prostate cancer presenting in a set-
ting with a low prevalence of screening. We thus here
identify a need for further development of statistical
methods to take competing risk into account in pro-
spective studies of risk factors for diseases with the pre-
valence peak late in life. The finding that smoking may
be a risk factor for prostate cancer in men with low
serum selenium levels is relevant to explore further. We
found indications that patterns of exposure to selenium
and smoking combined with data on genetic variation in
genes involved in DNA repair for oxidative damage can
be valuable to explore. Our findings are of relevance for
the analysis of interventional studies with selenium
supplementation.
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